Core Viewpoint - He Yuan Bio (688765.SH) reported a significant increase in total operating revenue for the fiscal year 2025, driven by the successful launch of its new product, Aofumin®, which was approved in July 2025 and quickly achieved sales breakthroughs [1] Financial Performance - The company achieved total operating revenue of 47.8614 million yuan, representing a year-on-year increase of 89.80% [1] - The net profit attributable to the parent company was -157.9449 million yuan, with losses increasing by 6.5768 million yuan year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -175.7542 million yuan, with losses increasing by 9.0068 million yuan year-on-year [1] Growth Drivers - The significant revenue growth was primarily due to the market promotion of Aofumin® and the increasing recognition of its clinical value by end-users [1] - The company continues to maintain a high level of investment in research and development to support the ongoing output of research results [1]
禾元生物(688765.SH)：2025年度净亏损1.58亿元